Although nisin is an antimicrobial peptide, nisA does not encode fully active nisin. The primary structure of NisA must be post-translationally modified in three critical ways before it shows antimicrobial activity.
First, the dehydratase NisB dehydrates certain residues on NisA (Fig. 1A). Second, the cyclase NisC forms five thioether bonds, giving nisin its distinctive structure with five rings (Fig. 1B). Both NisB and NisC specifically recognize the leader peptide sequence (23 of 57 total amino acids in NisA, on the N-terminus side). Third, the extracellular peptidase NisP cleaves the leader (Fig. 1C), leaving fully modified and active nisin (Fig. 1D) [1]. While NisB and NisC are required to produce active nisin and therefore must be co-expressed in our chassis, we altered the leader cleavage site to our advantage. The V8 protease is an extracellular protease produced by Staphylococcus aureus, one of the main pathogens in cellulitis infections. By changing the NisP cleavage site to a V8 cleavage site, we can make the pathogen work for us and against itself – during the production of NiSkin, we do not have to worry about the cleavage step. Instead, NiSkin will remain in an inactive form until it reaches the site of infection, where the V8 protease being released by S. aureus will cleave the leader peptide, leaving nisin with antibacterial activity.
From the literature, we know that TD-1 works best when fused to the N-terminus of the protein of interest [2]. However, TD-1 has never been tested with nisin, so the most effective way of linking the two proteins is unknown. To find the best method, we designed five different nisA genes. The first two are controls: one using the original primary structure found in Lactococcus lactis but with a V8 cleavage site and one with the original NisA primary structure (Figure 2A, 1B). The other three are variants of TD-1 fused with NisA: the first uses a truncated leader with TD-1 embedded between a truncated leader and the rest of NisA (Figure 2C); the second has TD-1 conjugated to the full leader (Figure 2D); the third has TD-1 conjugated to a glycine-serine linker conjugated to the full leader sequence (Figure 2E). All three TD-1-NisA fusion proteins use the V8 cleavage site for the leader. Additionally, all five proteins have an N-terminal His6 tag for purification purposes. With the sequences coding for NisB (Figure 2A-E) and NisC (Figure 2F), we have a total of seven different gene sequences. Because NisB and NisC do not serve any additional functions after modifying NisA and because epitope tags might interfere with enzymatic activity, NisB and NisC are untagged. All sequences were codon optimized for E. coli BL21(DE3).
All of our sequences were synthesized then amplified using PCR. nisA and nisB were inserted into the same open reading frame (ORF) on the pRSFDuet-1 vector. nisC was inserted into the pACYCDuet-1 vector. pRSFDuet-1 contains an RSF1030 replicon and pACYCDuet-1 contains a P15A replicon, making them compatible for transformation into the same chassis [3]. Plasmids were first transformed into E. coli DH5α cells for plasmid amplification, which was verified with restriction digests/gel electrophoresis and Sanger sequencing of the plasmids. Both plasmids were then transformed into E. coli BL21(DE3) cells, so we were ready to co-express the NisA variants alongside NisB and NisC.
After confirming proper plasmid insertion of pRSFDuet-1-nisA-nisB (and the other four variants) and pACYCDuet-1-nisC with a restriction digest and Sanger sequencing, the next step was to express our engineered NisA, NisB, and NisC. Both vectors use a T7 promoter system, allowing us to chemically induce transcription with IPTG and regulate the expression of our proteins. Protein samples were analyzed with SDS-PAGE, which confirmed that we are expressing proteins when E. coli BL21(DE3) cultures are induced with IPTG.
Analyzing our proteins by Western blot was not simple; there are no available antibodies against NisA, NisB, or NisC. However, for purification purposes, all of our NisA proteins have an N-terminal His6 tag. Thus, we then analyzed our NisA constructs on a Western blot using anti-His6 antibodies (Invitrogen, MA1-4806) and confirmed that we are producing NisA constructs that have the His6 tag.
We defined two criteria by which we wanted to quantitatively test our engineered nisin: antibacterial activity and skin permeability. An effective topically applied drug must both have strong antibacterial activity and be able to reach the site of infection at the correct dosage. After purifying our engineered nisin via affinity purification with the His6 tag, we could begin testing.
The disk diffusion assay is a well-proven method for studying antibacterial activity of different antibiotics. An agar plate is grown with an even lawn of bacteria and disks soaked with specific concentrations of antibiotic are placed on the plate. A ring of inhibition (no growth) will form around the disk; the larger the ring, the more effective the antibiotic. Nisin has already demonstrated strong activity against Staphylococcus aureus, one of the main pathogens in cellulitis infections [4,5]. A successful test will demonstrate that our engineered nisin is able to achieve a comparable level of antibacterial activity.
To test skin permeability, we are using a Franz diffusion assay. Using porcine skin to model human skin, we can measure how much of our engineered nisin is able to diffuse across the skin and to the theoretical site of infection. By comparing the permeation of nisin against our engineered nisin with TD-1, we can quantify how much TD-1 aids permeation. Additionally, this assay will tell us what concentration of NiSkin is necessary in a skin cream to deliver the correct dosage of nisin into the dermis.
(Adapted from Roche Ni NTA protocol https://www.studocu.com/row/document/)
In a beaker dissolve 242 g Tris base in 500 mL milliQ water, add 57.1 mL glacial acetic acid and 100 mL 0.5 M EDTA pH 8, transfer to graduated cylinder and add milliQ water until final volume is 1 L. Dilute in milliQ water for 1x working solution. The 1x working solution is 40 mM Tris/acetate and 1 mM EDTA.
Adapted from Cold Spring Harbor (http://m.cshprotocols.cshlp.org/content/2006/1/pdb.rec8644.full).
To 950 mL of dH2O, add: 10 g tryptone, 5 g yeast extract, 10 g NaCl. Shake until the solutes have dissolved. Adjust the pH to 7.0 with 5 N NaOH (~0.2 mL). Adjust the volume of the solution to 1 L with d H2O. Sterilize by autoclaving for 20 min at 15 psi on liquid cycl (From Sambrook and Russel. Molecular Cloning: A Laboratory Manual, 3rd e.d., Volume 3).
Fairbanks IIn 900 mL dH2O, dissolve 144 g glycine, 30 g Tris base, and 5 g SDS. Add dH2O up to 1 L.
In 700 mL dH2O, dissolve 3.03 g Tris base and 14.4 g glycine. Add dH2O up to 800 mL. Add 200 mL methanol for final concentration 20% v/v and final volume 1 L.
Make a 100 mM stock of PMSF in ethanol. Store at 4°C.
Make Sonication Buffer fresh for each fractionation. To make 5 mL Sonication Buffer, add 83.3 µL 0.6 M sodium phosphate buffer pH 7 and 50 µL 100 mM PMSF to 4.867 mL milliQ water.
Dissolve 8 g of NaCl, 0.2 g KCl, and 3 g of Tris base in 800 mL of dH2O. Add 0.015 g of phenol red and adjust the pH to 7.4 with HCl. Add dH2O to 1 L. Sterilize by autoclaving for 20 minutes at 15 psi on liquid cycle. Store buffer at room temperature. (From Sambrook & Russell. Molecular Cloning: A Laboratory Manual, 3rd e.d., Volume 3). To create Tris-Buffered Saline with Tween 20 (TBST), add 0.01% v/v Tween 20 to TBS.
Prepare 1 M Dibasic Sodium Phosphate and 1 M Monobasic Sodium Phosphate solutions. To create Buffer of pH 7, add 57.7% Dibasic Sodium Phosphate v/v and 42.3% v/v Monobasic Sodium Phosphate. Dilute with dH2O to create lower concentration buffers.
In a 2 L Erlenmeyer flask, dissolve 5 g Pancreatic Digest of Casein, 5 g Soy Peptone, 5 g Beef Extract, 2.5 g Yeast Extract, 0.5 g Ascorbic Acid, 0.25 g MgSO4, 0.25 g Disodium-B-glycerophosphate, and 11 g Agar in dH2O up to final volume 861 mL. Adjust pH to 6 with HCl. Heat with stirring and boil for 1 minute to completely dissolve reagents. Autoclave the solution for 20 minutes at 15 psi on liquid cycle. When solution has cooled to 50°C, add 50 mL sterile 10% lactose solution and 89 mL sterile 25% w/v glucose. Pour solution into plates and let solidify overnight. Store upside down at 4°C. (Adapted from Difco and BBL Manual of Microbiological Culture Media, 2nd e.d.).
Phosphate-Buffered Saline (PBS)Dissolve 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2PO4, and 0.24 g of KH2PO4 in 800 mL of dH2O. Adjust the pH to 7.4 with HCl. Add dH2O to 1 L. Sterilize by autoclaving for 20 minutes at 15 psi on liquid cycle or by filter sterilization. Store the buffer at room temperature. (From Sambrook & Russell. Molecular Cloning: A Laboratory Manual, 3rd e.d., Volume 3).